General MedicationsINTRAVENOUSStandard
NIKTIMVO
axatilimab-csfr
Standard Dose
50 MG/ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary
Approval overview NIKTIMVO is listed in Drugs@FDA under application 761411 (BLA).
Review priority: PRIORITY Marketing status: Prescription Active ingredient axatilimab-csfr Form and strength INJECTABLE;INTRAVENOUS - 50 MG/ML Sponsor INCYTE CORP Submission history Latest submission status date: 2024-08-14 00:00:00.
Structured Monograph
Clinical summary
Approval overview NIKTIMVO is listed in Drugs@FDA under application 761411 (BLA). Review priority: PRIORITY Marketing status: Prescription Active ingredient axatilimab-csfr Form and strength INJECTABLE;INTRAVENOUS - 50 MG/ML Sponsor INCYTE CORP Submission history Latest submission status date: 2024-08-14 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.